In May 2025, Careteq Limited (ASX: CTQ) a clinical healthtech company specialising in medication management and clinical governance solutions announced details of a disputed R&D claim. The May 2025 announcement noted that Careteq: ‘advises that it has been issued with amended assessments from the Australian Taxation Office (ATO) in relation to claims made under the Australian government’s Research and Development Research and Development Tax Incentive (R&D Tax Incentive)for the financial years ended 30 June 2021, 2022 and 2023 (Amended Assessments). The Amended […]
The ATO has updated guidance on 13 July 2026 around the provisions for R&D activities conducted for an associated foreign corporation. To be eligible to claim the R&D tax incentive for R&D activities conducted for one or more associated foreign corporations, the following conditions must apply: Each foreign corporation must be a resident of a foreign country that has a double tax agreement with Australia. The R&D activity must be conducted solely in Australia or an external territory of Australia. If the R&D activity is a supporting […]